Compounded GLP-1: what it actually is, in plain English

In the United States, the medications most adults associate with weight management — the GLP-1 receptor agonists — are sold as finished branded products manufactured by large pharmaceutical companies. Those finished products go through the full FDA new drug approval pathway, are produced in cGMP facilities at industrial scale, and are labeled for specific indications. Compounded GLP-1 is something legally and practically distinct. It is a preparation made by a licensed pharmacy, for a specific patient, from active pharmaceutical ingredient (API) plus excipients, under the authority of a prescriber and a state board of pharmacy.

That distinction matters. It is the entire reason this category of medicine exists, and it is the reason the language on Form’s site is careful: compounded GLP-1 is compounded under section 503A of the FD&C Act; compounded GLP-1 is NOT FDA-approved as a finished product.

What “section 503A” actually means

Section 503A of the Federal Food, Drug, and Cosmetic Act is the part of US law that carves out a legal space for traditional pharmacy compounding. The short version: a licensed pharmacist (or licensed physician) can prepare a medication for an individually identified patient, pursuant to a valid prescription, using bulk drug substances that meet certain criteria. The pharmacy is regulated primarily by its state board of pharmacy, and the FDA retains jurisdiction over adulteration, misbranding, and the conditions under which compounding may occur.

503A is not a loophole. It is the framework that allows pharmacists to make a dye-free version of a child’s antibiotic, a preservative-free eye drop for a patient with a specific allergy, or — in this category — an injectable GLP-1 preparation titrated to a patient who could not tolerate the standard finished-product dose. The defining feature is the patient-specific prescription. There is no compounded GLP-1 that exists “off the shelf” for whoever wants it; legally there cannot be.

Why a pharmacy makes it (and why now)

Compounding is centuries older than mass-manufactured pharmaceuticals, but the specific reason patients are encountering compounded GLP-1 today comes down to three forces that converged over the last several years: clinical demand, supply limitations on branded finished products, and the FDA’s drug shortage list. When the FDA places a drug on its official shortage list, federal rules permit compounding pharmacies to prepare a version using bulk API, provided the other 503A conditions are satisfied. That list status has changed over time and is best checked directly against current FDA publications; the framework, however, has not changed.

In practice, a 503A pharmacy that prepares compounded semaglutide or compounded tirzepatide does the following:

• Sources active pharmaceutical ingredient from an FDA-registered facility and obtains a certificate of analysis for each lot.
• Performs sterility, endotoxin, and potency testing through accredited third-party labs on representative samples.
• Compounds the preparation under USP <797> standards for sterile compounding, with documented hood time, gowning, and environmental monitoring.
• Dispenses the preparation only against a valid, patient-specific prescription from a licensed clinician.

None of that is the same as cGMP manufacturing at a Novo Nordisk or Lilly plant. It is not meant to be. It is a different regulatory category, doing a different job, for different patients.

Who can actually prescribe it

Only a clinician licensed in the patient’s state can issue a valid prescription. On Form, that means an independent physician, nurse practitioner, or physician assistant contracted through our medical group partner, holding an active license in the state where the patient lives. The platform itself does not prescribe. The quiz does not prescribe. A telehealth visit is required, the clinician reviews the patient’s history, contraindications, and labs where appropriate, and either issues a prescription or declines.

What clinicians are actually checking

The eligibility review is more than a BMI calculation. A responsible clinician is evaluating personal and family medical history for thyroid cancer, pancreatitis, severe gastroparesis, gallbladder disease, current or planned pregnancy, eating disorder history, and the medications you are already taking. They are also assessing whether a GLP-1 is genuinely the right tool for this patient at this time, or whether behavioral support, a different medication, or referral elsewhere is more appropriate.

How it differs from a finished branded product

The clearest, most honest framing is that compounded GLP-1 and finished branded GLP-1 products are not the same product and are not interchangeable. The active drug substance in compounded semaglutide is semaglutide; the active drug substance in compounded tirzepatide is tirzepatide. But that is also true of generic acetaminophen and brand-name Tylenol, and we still do not call them the same product because the regulatory pathway, the finished formulation, the labeling, and the testing regime all differ.

• Regulatory pathway: finished branded products go through FDA new drug approval; 503A compounded preparations do not.
• Manufacturing scale: branded products are made in cGMP plants; compounded preparations are made in pharmacy clean rooms under USP <797>.
• Prescription model: branded products are dispensed against any valid prescription; compounded preparations require a patient-specific prescription tied to a clinical rationale.
• Formulation: some compounded preparations include additional ingredients such as B12, vitamin B6, or specific buffers; the branded finished product has a fixed formulation.

Boxed warning: Risk of thyroid C-cell tumors. Do not use if you or a family member have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

The practical takeaway

If you are an adult considering compounded GLP-1 therapy, the questions worth asking are not “is this the same as the brand?” — it is not, and any platform telling you otherwise is misrepresenting the regulation. The better questions are: which state-licensed 503A pharmacy is preparing it, what testing do they perform, what licensure does the prescribing clinician hold, and what is the clinical plan if you do not tolerate the dose or do not respond. Those are the answers that determine whether a program is worth your time and money. The rest is marketing.

At Form, our role is to make that information legible. The compounded preparation is dispensed by a state-licensed 503A pharmacy partner. The prescribing clinician is independently licensed in your state. The plan is reviewed and titrated based on your tolerance and response, not on a script. None of that makes a GLP-1 right for every adult — but it makes the question askable.